for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CareDx Inc

CDNA.OQ

Latest Trade

21.21USD

Change

0.34(+1.63%)

Volume

192,341

Today's Range

20.58

 - 

21.34

52 Week Range

18.75

 - 

41.27

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
20.87
Open
21.02
Volume
192,341
3M AVG Volume
17.22
Today's High
21.34
Today's Low
20.58
52 Week High
41.27
52 Week Low
18.75
Shares Out (MIL)
42.42
Market Cap (MIL)
885.64
Forward P/E
290.43
Dividend (Yield %)
--

Latest Developments

More

Caredx Reports Q3 Loss Per Share Of $0.04

CareDx Files Patent Infringement Lawsuit Against Eurofins Viracor

CareDx Reports Q2 Loss Per Share $0.19

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About CareDx Inc

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Industry

Healthcare Facilities

Contact Info

3260 Bayshore Blvd

+1.415.2872300

http://www.caredxinc.com/

Executive Leadership

Michael D. Goldberg

Independent Chairman of the Board

Reginald Seeto

President, Chief Business Officer

Peter Maag

Chief Executive Officer, Director

Michael Bell

Chief Financial Officer

Sasha King

Chief Commercial Officer

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2016

-0.840

2017

-0.690

2018

-0.150

2019(E)

0.070
Price To Earnings (TTM)
--
Price To Sales (TTM)
7.72
Price To Book (MRQ)
9.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-22.11
Return on Equity (TTM)
-17.73

Latest News

Latest News

BRIEF-Caredx Inc Enters Into A License And Commercialization Agreement With Illumina

* CAREDX INC - ON MAY 4, 2018, CO ENTERED INTO A LICENSE AND COMMERCIALIZATION AGREEMENT WITH ILLUMINA, INC - SEC FILING

BRIEF-Caredx Enters Into A Credit Agreement And Guaranty - SEC Filing

* CAREDX SAYS ON APRIL 17 ENTERED INTO A CREDIT AGREEMENT AND GUARANTY - SEC FILING

BRIEF-Caredx Launches Heartcare For Heart Transplant Recipients

* ANNOUNCED LAUNCH OF HEARTCARE, A COMPREHENSIVE REJECTION SURVEILLANCE SOLUTION FOR HEART TRANSPLANT RECIPIENTS Source text for Eikon: Further company coverage:

BRIEF-CareDx Q4 Non-Gaap Loss Per Share $0.09

* FY2018 REVENUE VIEW $61.5 MILLION -- THOMSON REUTERS I/B/E/S

BRIEF-Caredx - Entered Binding Commitment With Perceptive Advisors For Term Loan Of Between $15 Mln And $35 Mln

* CAREDX - ENTERED BINDING COMMITMENT WITH PERCEPTIVE ADVISORS FOR A TERM LOAN OF BETWEEN $15 MILLION AND $35 MILLION

BRIEF-Caredx Sees FY 2017 Revenue $48.1 Mln To $48.3 Mln

* CAREDX REPORTS PRELIMINARY FOURTH QUARTER AND FY2017 FINANCIAL RESULTS

BRIEF-Caredx reports third quarter loss of $0.63 per share

* Sees fy 2017 revenue $47 million to $49 million Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Biocardia announces reverse stock split and release of indemnity holdback shares

* Biocardia announces reverse stock split and release of indemnity holdback shares

BRIEF-CareDx closes public offering of common stock

* CareDx announces closing of public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Caredx entered into an underwriting agreement with Craig-Hallum Capital Group - SEC filing

* Caredx Inc - on October 4, co entered into an underwriting agreement with Craig-Hallum capital Group LLC - SEC filing

BRIEF-CareDx says currently offering of up to 3.6 mln shares versus previously expected offering of up to 3 mln shares

* CareDx Inc says currently offering of up to 3.6 million shares of common stock versus previously expected offering of up to 3.0 million shares of common stock Source: (http://bit.ly/2xTuyf5) Further company coverage:

BRIEF-CareDx files for offering of 3 million shares of its common stock - SEC filing

* Files for offering of 3 million shares of its common stock - SEC filing Source text: [http://bit.ly/2iOXsaP] Further company coverage:

BRIEF-CareDx Inc files prospectus related to resale of 2.8 million shares of common stock by selling stockholders

* CareDx Inc files prospectus related to resale of 2.8 million shares of common stock by selling stockholders - SEC filing Source text : (http://bit.ly/2vwR9JY) Further company coverage:

BRIEF-CareDx reports Q2 loss per share $0.19

* Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Caredx Q1 non-gaap loss per share $0.32

* Q1 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S

BRIEF-CareDX reports Q1 loss per share $0.26

* Q1 earnings per share view $-0.22, revenue view $11.3 million -- Thomson Reuters I/B/E/S Source text: (http://bit.ly/2s3G3hs) Further company coverage:

BRIEF-BioCardia Inc files for mixed shelf of up to $50.0 million

* BioCardia Inc files for mixed shelf of up to $50.0 million - SEC filing Source text for Eikon: (http://bit.ly/2rAzQXM) Further company coverage:

BRIEF-Caredx files for resale of up to 8.25 mln shares of co's common stock

* Files for resale of up to 8.25 million shares of co's common stock by the selling stockholders - SEC filing Source text for Eikon: Further company coverage:

BRIEF-CareDx appoints Michael Bell chief financial officer

* CareDx Inc - constanti will remain with company until june 30th to facilitate a smooth transition Source text for Eikon: Further company coverage:

BRIEF-CareDx reports Q4 loss per share $0.73

* CareDx Inc - for full year 2017, company continues to expect revenue to be in range of $45 million to $50 million, excluding any potential allosure revenue

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up